Clinical Overview
Levomilnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of major depressive disorder in adults. It is the active enantiomer of milnacipran and demonstrates potent inhibition of both serotonin and norepinephrine reuptake with greater selectivity for norepinephrine.
Primary Clinical Applications
Levomilnacipran is indicated specifically for major depressive disorder in adults. Its balanced dual reuptake inhibition may provide benefits for patients with depression accompanied by fatigue, low energy, or concentration difficulties. The medication has shown efficacy in improving both emotional and physical symptoms of depression.
Mechanism and Pharmacological Profile
Unlike other SNRIs, levomilnacipran exhibits approximately 2-fold greater potency for norepinephrine reuptake inhibition compared to serotonin reuptake inhibition. This unique profile may contribute to its efficacy in treating depression-related fatigue and cognitive symptoms.
Clinical Considerations
Levomilnacipran requires gradual dose titration and should be taken with food to improve tolerability. The extended-release formulation allows for once-daily dosing, which may improve medication adherence in patients with depression.
Prescribing Information
Dosing & Administration
Major Depressive Disorder – Adults:
- Initial: 20 mg once daily for 2 days
- Target dose: 40 mg once daily (starting day 3)
- Range: 40-120 mg once daily
- Titration: May increase by 40 mg increments at intervals ≥2 days
- Maximum: 120 mg once daily
Administration:
- Take with or without food
- Swallow capsules whole, do not open or chew
- Take at the same time each day
Indications
- Major depressive disorder in adults
Contraindications
- Hypersensitivity to levomilnacipran, milnacipran, or any component
- Use with MAOIs (within 14 days of discontinuation)
- Use with linezolid or IV methylene blue
Warnings & Precautions
- Boxed Warning: Increased risk of suicidal thoughts and behavior in patients under 25 years
- Serotonin syndrome risk, especially with concurrent serotonergic drugs
- Elevated blood pressure and heart rate: Monitor cardiovascular parameters
- Angle-closure glaucoma: Pupillary dilation may trigger attack
- Hyponatremia and SIADH
- Discontinuation syndrome: Taper gradually
Drug Interactions
- MAOIs: Contraindicated – risk of serotonin syndrome
- Serotonergic drugs: Increased risk of serotonin syndrome
- NSAIDs, aspirin: Increased bleeding risk
- Digoxin: Monitor digoxin levels
Adverse Reactions
Common (≥5%):
- Nausea, constipation, hyperhidrosis, heart rate increased
- Erectile dysfunction, tachycardia, vomiting
Cardiovascular:
- Hypertension, palpitations, increased heart rate
Special Populations
- Renal Impairment: Moderate: Maximum 80 mg daily; Severe: Maximum 40 mg daily
- Hepatic Impairment: No dose adjustment for mild-moderate impairment
- Pregnancy: Category C – use only if benefits outweigh risks
- Elderly: No specific dose adjustment, but monitor closely
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
